Serina Therapeutics appoints Dr. Jay Venkatesan to its Board, enhancing strategic leadership for drug development initiatives.
Quiver AI Summary
Serina Therapeutics, Inc. has announced the appointment of Dr. Jay Venkatesan, a seasoned expert in biotechnology investment and company growth, to its Board of Directors. Dr. Venkatesan, who previously held leadership positions in several biopharma companies including Angion Biomedica and Alpine Immune Sciences, will bring significant expertise in corporate strategy and capital markets to Serina. The company's CEO, Steve Ledger, highlighted Dr. Venkatesan's experience in transformative business transactions as a key asset as Serina advances its proprietary POZ Platform™ aimed at developing innovative therapeutics. Additionally, Serina’s co-founder, Dr. Milton Harris, will transition to a role as Director Emeritus and Chair of the Scientific Advisory Board, continuing to guide the company’s research and development efforts.
Potential Positives
- Appointment of Dr. Jay Venkatesan to the Board of Directors enhances Serina's leadership with his extensive experience in biotechnology investment and strategic growth.
- Dr. Venkatesan's proven track record in guiding biopharma companies through pivotal stages, including high-profile mergers and acquisitions, adds significant credibility to Serina's strategic vision.
- The transition of co-founder Dr. Milton Harris to Director Emeritus and Chair of the Scientific Advisory Board ensures continued leadership and expertise in guiding Serina's research and development efforts.
Potential Negatives
- The appointment of Dr. Jay Venkatesan, while showcasing his extensive experience, may highlight Serina Therapeutics' need for strategic guidance, suggesting potential struggles in navigating its development pipeline effectively.
- The transition of co-founder Dr. Milton Harris to Director Emeritus may signal a significant shift in leadership dynamics, potentially raising concerns about continuity and strategic direction within the company.
- The mention of substantial risks and uncertainties associated with the company's forward-looking statements may indicate that investors should be wary of the company's future prospects and the viability of its drug development efforts.
FAQ
Who is Jay Venkatesan?
Jay Venkatesan, MD, MBA, is a biotechnology expert appointed to Serina Therapeutics' Board of Directors, bringing leadership experience in the biopharma sector.
What is Serina Therapeutics' POZ Platform?
The POZ Platform™ is Serina's proprietary drug optimization technology aimed at improving efficacy and safety for various therapeutic modalities.
What previous roles did Jay Venkatesan have?
Dr. Venkatesan previously served as CEO of Angion Biomedica and was co-founder and President of Alpine Immune Sciences.
How will Jay Venkatesan contribute to Serina Therapeutics?
He will leverage his expertise in corporate strategy and business development to guide Serina's pipeline advancement and strategic growth.
What is the focus of Serina Therapeutics?
Serina Therapeutics focuses on developing drug candidates for neurological diseases and other indications using its innovative POZ Platform technology.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$SER Insider Trading Activity
$SER insiders have traded $SER stock on the open market 15 times in the past 6 months. Of those trades, 15 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $SER stock by insiders over the last 6 months:
- GREGORY BAILEY has made 9 purchases buying 46,767 shares for an estimated $312,850 and 0 sales.
- STEVEN MINTZ has made 6 purchases buying 14,943 shares for an estimated $97,742 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$SER Hedge Fund Activity
We have seen 8 institutional investors add shares of $SER stock to their portfolio, and 7 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WAVERLY ADVISORS, LLC added 44,007 shares (+187.4%) to their portfolio in Q3 2024, for an estimated $294,406
- KEEL POINT, LLC added 17,774 shares (+inf%) to their portfolio in Q3 2024, for an estimated $118,908
- VANGUARD GROUP INC added 17,573 shares (+39.5%) to their portfolio in Q4 2024, for an estimated $88,040
- NORTHERN TRUST CORP added 14,787 shares (+inf%) to their portfolio in Q3 2024, for an estimated $98,925
- MILLENNIUM MANAGEMENT LLC removed 2,416 shares (-11.1%) from their portfolio in Q3 2024, for an estimated $16,163
- GEODE CAPITAL MANAGEMENT, LLC added 2,170 shares (+9.0%) to their portfolio in Q4 2024, for an estimated $10,871
- TOWER RESEARCH CAPITAL LLC (TRC) removed 1,151 shares (-58.9%) from their portfolio in Q3 2024, for an estimated $7,700
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
HUNTSVILLE, AL, Feb. 12, 2025 (GLOBE NEWSWIRE) --
Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform
™
drug optimization technology, today announced the appointment of Jay Venkatesan, MD, MBA, to its Board of Directors. Dr. Venkatesan brings deep expertise in biotechnology investment, company building, and strategic growth, having successfully led and advised multiple biopharma companies through pivotal stages of development, including high-profile mergers and acquisitions.
Dr. Venkatesan most recently served as Chairman, President, and CEO of Angion Biomedica until its merger with Elicio Therapeutics in 2023. He currently serves as a Board Director at Elicio Therapeutics. Previously, he was President and Board Director of Alpine Immune Sciences, which he co-founded as a Managing Partner of Alpine BioVentures. Alpine Immune Sciences was acquired by Vertex Pharmaceuticals for $4.9 billion in May 2024.
“Jay’s extensive leadership experience in biotechnology, particularly in corporate strategy, business development, and capital markets, makes him an invaluable addition to Serina’s Board,” said Steve Ledger, CEO of Serina Therapeutics. “His track record in advancing innovative therapies and successfully guiding companies through transformational transactions aligns with our mission to develop best-in-class therapeutics. We look forward to leveraging his insights as we advance our pipeline and explore strategic growth opportunities for our platform.”
Dr. Venkatesan has a distinguished career spanning investment and operational leadership roles. Before Alpine, he founded and managed Ayer Capital, a global healthcare investment fund. Earlier in his career, he was a director at Brookside Capital, a division of Bain Capital, where he co-managed healthcare investments. He also held roles as a venture investor with Patricof & Co. Ventures (now Apax Partners) and as a consultant at McKinsey & Co.
Dr. Venkatesan holds an M.D. from the University of Pennsylvania School of Medicine and an M.B.A. from the Wharton School of the University of Pennsylvania. He earned his B.A. from Williams College.
“I am excited to join the Board of Serina Therapeutics at such a dynamic time for the company,” said Dr. Venkatesan. “Serina’s innovative approach to drug development, leveraging its proprietary POZ polymer technology, holds great promise in addressing unmet needs across multiple therapeutic areas. I look forward to contributing to the company’s continued success and helping guide its strategic vision.”
Serina’s co-founder, Dr. Milton Harris, will assume the role of Director Emeritus and will serve as Chair of the company’s Scientific Advisory Board (SAB). Dr. Harris has played an instrumental role in the development of Serina’s POZ Platform, providing leadership and scientific expertise that have shaped the company’s pipeline and clinical development. In his new role, he will provide continued guidance to Serina’s research and development efforts.
About Serina Therapeutics
Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina’s POZ Platform
™
provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology.
For more information, please visit
https://serinatherapeutics.com
.
Cautionary Statement Regarding Forward-Looking Statement
This release contains forward-looking statements within the meaning of federal securities laws. These statements are based on management’s current expectations, plans, beliefs or forecasts for the future, and are subject to uncertainty and changes in circumstances. Any express or implied statements in this press release that are not statements of historical fact, including statements about the potential of Serina’s POZ polymer technology, are forward-looking statements that involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things discussed in the company’s Annual Report on Form 10-K for the year ended December 31, 2023, the company’s Current Report on Form 8-K that was filed with the SEC on April 1, 2024, and the company’s other periodic reports and documents filed from time to time with the SEC. The information contained in this release is as of the date hereof, and Serina assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
For inquiries, please contact:
Stefan Riley
sriley@serinatherapeutics.com
(256) 327-9630
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
